NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: AXIM Biotechnologies Engages Dr. Alan J. Touch and 624 Advisors as Chief Medical & Regulatory Affairs Advisor
TL;DR
AXIM Biotechnologies gains a strategic advantage by engaging Dr. Alan Touch, enhancing regulatory strategy and accelerating commercialization for its diagnostic tests.
AXIM Biotechnologies engages Dr. Alan Touch's consultancy to strengthen its regulatory, quality, and clinical execution processes for upcoming FDA submissions and global expansion.
This advisory role supports AXIM's development of better diagnostic tools, potentially improving treatment outcomes for patients with ocular and inflammatory diseases worldwide.
Dr. Alan Touch, inventor of the world's first colored contact lens, now advises AXIM Biotechnologies on advancing its rapid diagnostic test platform.
Found this article helpful?
Share it with your network and spread the knowledge!
AXIM Biotechnologies has engaged 624 Advisors, which is owned and managed by Dr. Alan J. Touch, as Chief Medical & Regulatory Affairs Advisor to provide regulatory and technical expertise.
Dr. Alan J. Touch is a preeminent IVD and CDx SME and global regulatory specialist with over three decades of leadership in diagnostics, medical devices, pharmaceuticals, and digital health. He is the original co-inventor of AXIM's first ocular diagnostic technologies, inventor of the world's first colored contact lens, and has held senior roles at Bausch & Lomb and INC Research (Syneos Health).
624 Advisors is a product development, regulatory and quality compliance consultancy founded by Dr. Alan J. Touch that provides AXIM with enhanced technical continuity, regulatory depth, and strategic execution capability.
This engagement strengthens AXIM's regulatory strategy, quality foundation, and clinical execution while positioning the company for efficient global expansion and long-term operational scale as it advances toward key regulatory and commercial milestones.
Dr. Touch brings inventor-level knowledge of AXIM's technology, significant senior-level experience in FDA regulation, ISO quality systems, clinical development, manufacturing readiness, and deep experience across FDA, EU MDR/IVDR, and global regulatory frameworks.
AXIM is advancing toward upcoming FDA 510(k) submissions, international regulatory expansion, and the establishment of a robust quality and manufacturing infrastructure.
Dr. Touch's background aligns with AXIM's efforts through his inventor-level understanding of lactoferrin and immunoassay diagnostics, proven leadership in regulatory affairs and quality systems, and knowledge to build milestone-based product development value propositions.
According to CEO Catalina Valencia, Dr. Touch's involvement strengthens AXIM's regulatory strategy, quality foundation, and clinical execution while positioning the company for efficient global expansion and long-term operational scale.
Dr. Touch stated he is pleased to work with AXIM at this important stage to continue advancing technology he originally helped develop, and he looks forward to supporting the team as they advance key submissions, strengthen quality systems, and prepare for manufacturing and commercial success.
AXIM Biotechnologies is a diagnostic and biotechnology company that advances clinically validated solutions for ocular and inflammatory diseases.
Curated from NewMediaWire
